Peptide-based radiopharmaceuticals for targeted tumor therapy

Current Medicinal Chemistry

Volumn 21, Issue 1, 2014, Pages 139-152

  Dong, C ^a,b   Liu, Z ^a,b   Wang, F ^a,b  

^a PEKING UNIVERSITY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Peptide receptor radionuclide therapy.; Radiotracer; Targeted therapy; Tumor

Indexed keywords

ANTINEOPLASTIC AGENT; ASTATINE 211; BISMUTH 212; BISMUTH 213; COPPER 64; COPPER 67; FLUOROURACIL; GALLIUM 67; GALLIUM 68; INDIUM 111; IODINE 131; LANREOTIDE TETRAXETAN Y 90; LUTETIUM 177; OCTREOTIDE; OCTREOTIDE[3 TYROSINE]; PENTETREOTIDE IN 111; PEPTIDE; RADIOPHARMACEUTICAL AGENT; RHENIUM 186; RHENIUM 188; SOMATOSTATIN DERIVATIVE; TETRAXETAN 3 PROLYLARGINYLGLYCYL ASPARTIC ACID 2 Y 90; TETRAXETAN ARGINYLGLYCYL ASPARTIC ACID 4 Y 90; TETRAXETAN OCTREOTIDE[3 TYROSINE] LU 177; TETRAXETAN OCTREOTIDE[3 TYROSINE] Y 90; TETRAXETAN[3 TYROSINE]OCTREOTATE LU 177; TETRAXETAN[3 TYROSINE]OCTREOTATE Y 90; UNCLASSIFIED DRUG; YTTRIUM 90;

ARTICLE; BINDING AFFINITY; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); COORDINATION; DOSIMETRY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; DRUG TARGETING; EXTRACELLULAR MATRIX; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; GASTROINTESTINAL TUMOR; HUMAN; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; LINEAR ENERGY TRANSFER; LIVER CELL CARCINOMA; LUNG SMALL CELL CANCER; MELANOMA; MENINGIOMA; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NAUSEA; NEOPLASM; NEUROENDOCRINE TUMOR; NONHODGKIN LYMPHOMA; NONHUMAN; OVERALL SURVIVAL; PANCREAS TUMOR; PARAGANGLIOMA; PROCESS OPTIMIZATION; PROGRESSION FREE SURVIVAL; PROTEIN TARGETING; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; THERAPY; TREATMENT RESPONSE; TUMOR REGRESSION; UNSPECIFIED SIDE EFFECT; VOMITING;

ANIMALS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PEPTIDES; RADIOPHARMACEUTICALS; RECEPTORS, PEPTIDE;

EID: 84889589885     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/09298673113209990219     Document Type: Article

References (119)

1. Culler, M.D.; Oberg, K.; Arnold, R.; Krenning, E.P.; Sevilla, I.; Diaz, J.A. Somatostatin Analogs for the Treatment of Neuroendocrine Tumors. Cancer Metastasis Rev., 2011, 30 Suppl 1, 9-17.
2. Ferro-Flores, G.; Ramirez Fde, M.; Melendez-Alafort, L.; Santos-Cuevas, C.L. Peptides for in vivo target-specific cancer imaging. Mini. Rev. Med. Chem., 2010, 10, 87-97.
3. Pool, S.E.; Krenning, E.P.; Koning, G.A.; van Eijck, C.H.; Teunissen, J.J.; Kam, B.; Valkema, R.; Kwekkeboom, D.J.; de Jong, M. Preclinical and clinical studies of peptide receptor radionuclide therapy. Semin. Nucl. Med., 2010, 40, 209-218.
4. Nanda, P.K.; Lane, S.R.; Retzloff, L.B.; Pandey, U.S.; Smith, C.J. Radiolabeled regulatory peptides for imaging and therapy. Curr. Opin. Endocrinol. Diabetes Obes., 2010, 17, 69-76.
5. Bodei, L.; Ferone, D.; Grana, C.M.; Cremonesi, M.; Signore, A.; Dierckx, R.A.; Paganelli, G. Peptide receptor therapies in neuroendocrine tumors. J. Endocrinol. Invest., 2009, 32, 360-369.
6. Hoffman, T.J.; Quinn, T.P.; Volkert, W.A. Radiometallated receptor-avid peptide conjugates for specific in vivo targeting of cancer cells. Nucl. Med. Biol., 2001, 28, 527-539. (Pubitemid 32539402)
7. Karagiannis, T.C. Comparison of different classes of radionuclides for potential use in radioimmunotherapy. Hell. J. Nucl. Med., 2007, 10, 82-88. (Pubitemid 47342270)
8. Enger, S.A.; Hartman, T.; Carlsson, J.; Lundqvist, H. Cross-fire doses from beta-emitting radionuclides in targeted radiotherapy. A theoretical study based on experimentally measured tumor characteristics. Phys. Med. Biol., 2008, 53, 1909-1920. (Pubitemid 351570898)
9. Ginj, M.; Hinni, K.; Tschumi, S.; Schulz, S.; Maecke, H.R. Trifunctional somatostatin-based derivatives designed for targeted radiotherapy using auger electron emitters. J. Nucl. Med., 2005, 46, 2097-2103. (Pubitemid 46657459)
10. Miao, Y.; Hylarides, M.; Fisher, D.R.; Shelton, T.; Moore, H.; Wester, D.W.; Fritzberg, A.R.; Winkelmann, C.T.; Hoffman, T.; Quinn, T.P. Melanoma therapy via peptide-targeted {alpha}-radiation. Clin. Cancer Res., 2005, 11, 5616-5621. (Pubitemid 41060840)
11. Volkert, W.A.; Goeckeler, W.F.; Ehrhardt, G.J.; Ketring, A.R. Therapeutic radionuclides: production and decay property considerations. J. Nucl. Med., 1991, 32, 174-185.
12. O'Donoghue, J.A.; Bardies, M.; Wheldon, T.E. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J. Nucl. Med., 1995, 36, 1902-1909.
13. Schubiger, P.A.; Alberto, R.; Smith, A. Vehicles, chelators, and radionuclides: choosing the "building blocks" of an effective therapeutic radioimmunoconjugate. Bioconjug. Chem., 1996, 7, 165-179. (Pubitemid 3043435)
14. Cremonesi, M.; Ferrari, M.; Bodei, L.; Tosi, G.; Paganelli, G. Dosimetry in peptide radionuclide receptor therapy: a review. J. Nucl. Med., 2006, 47, 1467-1475. (Pubitemid 47544933)
15. Goffredo, V.; Paradiso, A.; Ranieri, G.; Gadaleta, C.D. Yttrium-90 (90Y) in the principal radionuclide therapies: an efficacy correlation between peptide receptor radionuclide therapy, radioimmunotherapy and transarterial radioembolization therapy. ten years of experience (1999-2009). Crit. Rev. Oncol. Hematol., 2011, 80, 393-410.
16. Kam, B.L.; Teunissen, J.J.; Krenning, E.P.; de Herder, W.W.; Khan, S.; van Vliet, E.I.; Kwekkeboom, D.J. Lutetium-labelled peptides for therapy of neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imaging, 2012, 39 Suppl 1, S103-112.
17. Miao, Y.; Quinn, T.P. Peptide-targeted radionuclide therapy for melanoma. Crit. Rev. Oncol. Hematol., 2008, 67, 213-228.
18. Dadachova, E. Cancer therapy with alpha-emitters labeled peptides. Semin. Nucl. Med., 2010, 40, 204-208.
19. Teunissen, J.J.; Kwekkeboom, D.J.; Valkema, R.; Krenning, E.P. Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours. Endocr. Relat. Cancer, 2011, 18 Suppl 1, S27-51.
20. Reisinger, I.; Bohuslavitzki, K.H.; Brenner, W.; Braune, S.; Dittrich, I.; Geide, A.; Kettner, B.; Otto, H.J.; Schmidt, S.; Munz, D.L. Somatostatin receptor scintigraphy in small-cell lung cancer: results of a multicenter study. J. Nucl. Med., 1998, 39, 224-227. (Pubitemid 28114504)
21. Lamberts, S.W.; van der Lely, A.J.; de Herder, W.W.; Hofland, L.J. Octreotide. N. Engl. J. Med., 1996, 334, 246-254. (Pubitemid 26030676)
22. Nicolas, G.; Giovacchini, G.; Muller-Brand, J.; Forrer, F. Targeted radiotherapy with radiolabeled somatostatin analogs. Endocrinol. Metab. Clin. North Am., 2011, 40, 187-204.
23. Van Essen, M.; Krenning, E.P.; De Jong, M.; Valkema, R.; Kwekkeboom, D.J. Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues in Patients with Somatostatin Receptor Positive Tumours. Acta Oncol., 2007, 46, 723-734. (Pubitemid 47123757)
24. Nisa, L.; Savelli, G.; Giubbini, R. Yttrium-90 DOTATOC therapy in GEP-NET and other SST2 expressing tumors: a selected review. Ann. Nucl. Med., 2011, 25, 75-85.
25. Kwekkeboom, D.J.; Mueller-Brand, J.; Paganelli, G.; Anthony, L.B.; Pauwels, S.; Kvols, L.K.; O'Dorisio T, M.; Valkema, R.; Bodei, L.; Chinol, M.; Maecke, H.R.; Krenning, E.P. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J. Nucl. Med., 2005, 46 Suppl 1, 62S-66S. (Pubitemid 47619020)
26. Kwekkeboom, D.J.; Kam, B.L.; van Essen, M.; Teunissen, J.J.; van Eijck, C.H.; Valkema, R.; de Jong, M.; de Herder, W.W.; Krenning, E.P. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr. Relat. Cancer, 2010, 17, R53-73.
27. Valkema, R.; De Jong, M.; Bakker, W.H.; Breeman, W.A.; Kooij, P.P.; Lugtenburg, P.J.; De Jong, F.H.; Christiansen, A.; Kam, B.L.; De Herder, W.W.; Stridsberg, M.; Lindemans, J.; Ensing, G.; Krenning, E.P. Phase I study of peptide receptor radionuclide therapy with In-DTPAoctreotide: the rotterdam experience. Semin. Nucl. Med., 2002, 32, 110-122. (Pubitemid 34311077)
28. Buscombe, J.R.; Caplin, M.E.; Hilson, A.J. Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors. J. Nucl. Med., 2003, 44, 1-6. (Pubitemid 36077704)
29. Anthony, L.B.; Woltering, E.A.; Espenan, G.D.; Cronin, M.D.; Maloney, T.J.; McCarthy, K.E. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin. Nucl. Med., 2002, 32, 123-132. (Pubitemid 34311078)
30. Stokkel, M.P.; Verkooijen, R.B.; Bouwsma, H.; Smit, J.W. Six month follow-up after 111In-DTPA-octreotide therapy in patients with progressive radioiodine non-responsive thyroid cancer: a pilot study. Nucl. Med. Commun., 2004, 25, 683-690. (Pubitemid 38901685)
31. Delpassand, E.S.; Sims-Mourtada, J.; Saso, H.; Azhdarinia, A.; Ashoori, F.; Torabi, F.; Espenan, G.; Moore, W.H.; Woltering, E.; Anthony, L. Safety and efficacy of radionuclide therapy with highactivity In-111 pentetreotide in patients with progressive neuroendocrine tumors. Cancer Biother. Radiopharm., 2008, 23, 292-300. (Pubitemid 351931457)
32. Otte, A.; Herrmann, R.; Heppeler, A.; Behe, M.; Jermann, E.; Powell, P.; Maecke, H.R.; Muller, J. Yttrium-90 DOTATOC: first clinical results. Eur. J. Nucl. Med., 1999, 26, 1439-1447. (Pubitemid 29515605)
33. Paganelli, G.; Zoboli, S.; Cremonesi, M.; Macke, H.R.; Chinol, M. Receptor-mediated radionuclide therapy with 90Y-DOTA-D-Phe1-Tyr3-Octreotide: preliminary report in cancer patients. Cancer Biother. Radiopharm., 1999, 14, 477-483. (Pubitemid 30029795)
34. Paganelli, G.; Zoboli, S.; Cremonesi, M.; Bodei, L.; Ferrari, M.; Grana, C.; Bartolomei, M.; Orsi, F.; De Cicco, C.; Macke, H.R.; Chinol, M.; de Braud, F. Receptor-mediated radiotherapy with 90YDOTA-D-Phe1-Tyr3-octreotide. Eur. J. Nucl. Med., 2001, 28, 426-434.
35. Paganelli, G.; Bodei, L.; Handkiewicz Junak, D.; Rocca, P.; Papi, S.; Lopera Sierra, M.; Gatti, M.; Chinol, M.; Bartolomei, M.; Fiorenza, M.; Grana, C. 90Y-DOTA-D-Phe1-Try3-octreotide in Therapy of Neuroendocrine Malignancies. Biopolymers, 2002, 66, 393-398.
36. De Jong, M.; Bakker, W.H.; Breeman, W.A.; Bernard, B.F.; Hofland, L.J.; Visser, T.J.; Srinivasan, A.; Schmidt, M.; Behe, M.; Macke, H.R.; Krenning, E.P. Pre-clinical comparison of DTPA0 octreotide, DTPA0,Tyr3 octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Int. J. Cancer, 1998, 75, 406-411. (Pubitemid 28100044)
37. Forrer, F.; Waldherr, C.; Maecke, H.R.; Mueller-Brand, J. Targeted Radionuclide Therapy with 90Y-DOTATOC in Patients with Neuroendocrine Tumors. Anticancer Res., 2006, 26, 703-707. (Pubitemid 43206037)
38. Merlo, A.; Hausmann, O.; Wasner, M.; Steiner, P.; Otte, A.; Jermann, E.; Freitag, P.; Reubi, J.C.; Muller-Brand, J.; Gratzl, O.; Macke, H.R. Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue 90Y-labeled DOTA0-DPhe1-Tyr3-octreotide (DOTATOC): a pilot study in human gliomas. Clin. Cancer Res., 1999, 5, 1025-1033. (Pubitemid 29233216)
39. Waldherr, C.; Pless, M.; Maecke, H.R.; Haldemann, A.; Mueller-Brand, J. The clinical value of 90Y-DOTA-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann. Oncol., 2001, 12, 941-945. (Pubitemid 32725766)
40. Waldherr, C.; Pless, M.; Maecke, H.R.; Schumacher, T.; Crazzolara, A.; Nitzsche, E.U.; Haldemann, A.; Mueller-Brand, J. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J. Nucl. Med., 2002, 43, 610-616. (Pubitemid 34507110)
41. Bodei, L.; Cremonesi, M.; Grana, C.; Rocca, P.; Bartolomei, M.; Chinol, M.; Paganelli, G. Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imaging, 2004, 31, 1038-1046. (Pubitemid 38915663)
42. Bodei, L.; Cremonesi, M.; Zoboli, S.; Grana, C.; Bartolomei, M.; Rocca, P.; Caracciolo, M.; Macke, H.R.; Chinol, M.; Paganelli, G. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur. J. Nucl. Med. Mol. Imaging, 2003, 30, 207-216. (Pubitemid 36686839)
43. Frilling, A.; Weber, F.; Saner, F.; Bockisch, A.; Hofmann, M.; Mueller-Brand, J.; Broelsch, C.E
44. Valkema, R.; Pauwels, S.; Kvols, L.K.; Barone, R.; Jamar, F.; Bakker, W.H.; Kwekkeboom, D.J.; Bouterfa, H.; Krenning, E.P. Survival and response after peptide receptor radionuclide therapy with [90Y-[DOTA0,Tyr3]]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin. Nucl. Med., 2006, 36, 147-156. (Pubitemid 43320450)
45. Bushnell, D.L., Jr.; O'Dorisio, T.M.; O'Dorisio, M.S.; Menda, Y.; Hicks, R.J.; Van Cutsem, E.; Baulieu, J.L.; Borson-Chazot, F.; Anthony, L.; Benson, A.B.; Oberg, K.; Grossman, A.B.; Connolly, M.; Bouterfa, H.; Li, Y.; Kacena, K.A.; LaFrance, N.; Pauwels, S.A. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J. Clin. Oncol., 2010, 28, 1652-1659.
46. Imhof, A.; Brunner, P.; Marincek, N.; Briel, M.; Schindler, C.; Rasch, H.; Macke, H.R.; Rochlitz, C.; Muller-Brand, J.; Walter, M.A. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue 90Y-DOTA-TOC in metastasized neuroendocrine cancers. J. Clin. Oncol., 2011, 29, 2416-2423.
47. Virgolini, I.; Britton, K.; Buscombe, J.; Moncayo, R.; Paganelli, G.; Riva, P. In-and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin. Nucl. Med., 2002, 32, 148-155. (Pubitemid 34311081)
48. Cwikla, J.B.; Sankowski, A.; Seklecka, N.; Buscombe, J.R.; Nasierowska-Guttmejer, A.; Jeziorski, K.G.; Mikolajczak, R.; Pawlak, D.; Stepien, K.; Walecki, J. Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study. Ann. Oncol., 2010, 21, 787-794.
49. van Essen, M.; Krenning, E.P.; Kam, B.L.; de Jong, M.; Valkema, R.; Kwekkeboom, D.J. Peptide-receptor radionuclide therapy for endocrine tumors. Nat. Rev. Endocrinol., 2009, 5, 382-393.
50. Kwekkeboom, D.J.; Bakker, W.H.; Kam, B.L.; Teunissen, J.J.; Kooij, P.P.; de Herder, W.W.; Feelders, R.A.; van Eijck, C.H.; de Jong, M.; Srinivasan, A.; Erion, J.L.; Krenning, E.P. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [[177Lu-DOTA(0),Tyr3]]octreotate. Eur. J. Nucl. Med. Mol. Imaging, 2003, 30, 417-422. (Pubitemid 36692868)
51. Kwekkeboom, D.J.; de Herder, W.W.; Kam, B.L.; van Eijck, C.H.; van Essen, M.; Kooij, P.P.; Feelders, R.A.; van Aken, M.O.; Krenning, E.P. Treatment with the radiolabeled somatostatin analog 177 Lu-DOTA 0,Tyr3octreotate: toxicity, efficacy, and survival. J. Clin. Oncol., 2008, 26, 2124-2130.
52. van Essen, M.; Krenning, E.P.; Kooij, P.P.; Bakker, W.H.; Feelders, R.A.; de Herder, W.W.; Wolbers, J.G.; Kwekkeboom, D.J. Effects of therapy with [[177Lu-DOTA(0),Tyr3]]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. J. Nucl. Med., 2006, 47, 1599-1606. (Pubitemid 47545024)
53. Wehrmann, C.; Senftleben, S.; Zachert, C.; Muller, D.; Baum, R.P. Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC. Cancer Biother. Radiopharm., 2007, 22, 406-416. (Pubitemid 47067899)
54. de Jong, M.; Breeman, W.A.; Bernard, B.F.; Bakker, W.H.; Schaar, M.; van Gameren, A.; Bugaj, J.E.; Erion, J.; Schmidt, M.; Srinivasan, A.; Krenning, E.P. [177Lu-DOTA(0),Tyr3] octreotate for so matostatin receptor-targeted radionuclide therapy. Int. J. Cancer, 2001, 92, 628-633. (Pubitemid 32385702)
55. Breeman, W.A.; Mearadji, A.; Capello, A.; Bernard, B.F.; van Eijck, C.H.; Krenning, E.P.; de Jong, M. Anti-tumor effect and increased survival after treatment with 177Lu-[DOTA0,Tyr3]octreotate in a rat liver micrometastases model. Int. J. Cancer, 2003, 104, 376-379. (Pubitemid 36249821)
56. Kwekkeboom, D.J.; Bakker, W.H.; Kooij, P.P.; Konijnenberg, M.W.; Srinivasan, A.; Erion, J.L.; Schmidt, M.A.; Bugaj, J.L.; de Jong, M.; Krenning, E.P. [177Lu-DOTA(0),Tyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients. Eur. J. Nucl. Med., 2001, 28, 1319-1325.
57. Forrer, F.; Uusijarvi, H.; Storch, D.; Maecke, H.R.; Mueller-Brand, J. Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC. J. Nucl. Med., 2005, 46, 1310-1316. (Pubitemid 43733480)
58. Brooks, P.C.; Clark, R.A.; Cheresh, D.A. Requirement of Vascular Integrin Alpha v Beta 3 for Angiogenesis. Science, 1994, 264, 569-571.
59. Cai, W.; Niu, G.; Chen, X. Imaging of integrins as biomarkers for tumor angiogenesis. Curr. Pharm. Des., 2008, 14, 2943-2973.
60. Liu, Z.; Wang, F.; Chen, X. Integrin Targeted Delivery of Radiotherapeutics. Theranostics, 2011, 1, 201-210.
61. Yoshimoto, M.; Ogawa, K.; Washiyama, K.; Shikano, N.; Mori, H.; Amano, R.; Kawai, K. Alpha(v)beta(3) integrin-targeting radionuclide therapy and imaging with monomeric RGD peptide. Int. J. Cancer, 2008, 123, 709-715. (Pubitemid 351898432)
62. Janssen, M.L.; Oyen, W.J.; Dijkgraaf, I.; Massuger, L.F.; Frielink, C.; Edwards, D.S.; Rajopadhye, M.; Boonstra, H.; Corstens, F.H.; Boerman, O.C. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. Cancer Res., 2002, 62, 6146-6151. (Pubitemid 35244464)
63. Janssen, M.; Frielink, C.; Dijkgraaf, I.; Oyen, W.; Edwards, D.S.; Liu, S.; Rajopadhye, M.; Massuger, L.; Corstens, F.; Boerman, O. Improved tumor targeting of radiolabeled RGD peptides using rapid dose fractionation. Cancer Biother. Radiopharm., 2004, 19, 399-404. (Pubitemid 39281331)
64. Liu, Z.; Wang, F.; Chen, X. Integrin alpha(v)beta(3)-targeted cancer therapy. Drug Dev. Res., 2008, 69, 329-339.
65. Liu, S. Radiolabeled cyclic RGD peptides as integrin alpha( v)beta(3)-targeted radiotracers: maximizing binding affinity via bivalency. Bioconjug. Chem., 2009, 20, 2199-2213.
66. Liu, Z.; Shi, J.; Jia, B.; Yu, Z.; Liu, Y.; Zhao, H.; Li, F.; Tian, J.; Chen, X.; Liu, S.; Wang, F. Two Y-labeled multimeric RGD peptides RGD4 and 3PRGD2 for integrin targeted radionuclide therapy. Mol. Pharm., 2011, 8, 591-599.
67. Zhang, H.; Chen, J.; Waldherr, C.; Hinni, K.; Waser, B.; Reubi, J.C.; Maecke, H.R. Synthesis and Evaluation of Bombesin Derivatives on the Basis of Pan-bombesin Peptides Labeled with Indium-111, lutetium-177, and yttrium-90 for Targeting Bombesin Receptorexpressing Tumors. Cancer Res., 2004, 64, 6707-6715. (Pubitemid 39302601)
68. de Visser, M.; Verwijnen, S.M.; de Jong, M. Update: improvement strategies for peptide receptor scintigraphy and radionuclide therapy. Cancer Biother. Radiopharm., 2008, 23, 137-157. (Pubitemid 351649281)
69. Smith, C.J.; Volkert, W.A.; Hoffman, T.J. Gastrin releasing peptide (GRP) receptor targeted radiopharmaceuticals: a concise update. Nucl. Med. Biol., 2003, 30, 861-868. (Pubitemid 38040995)
70. Gonzalez, N.; Moody, T.W.; Igarashi, H.; Ito, T.; Jensen, R.T. Bombesin-related peptides and their receptors: recent advances in their role in physiology and disease states. Curr. Opin. Endocrinol. Diabetes Obes., 2008, 15, 58-64.
71. Johnson, C.V.; Shelton, T.; Smith, C.J.; Ma, L.; Perry, M.C.; Volkert, W.A.; Hoffman, T.J. Evaluation of combined (177)Lu-DOTA-8-AOC-BBN (7-14)NH(2) GRP receptor-targeted radiotherapy and chemotherapy in PC-3 human prostate tumor cell xenografted SCID mice. Cancer Biother. Radiopharm., 2006, 21, 155-166. (Pubitemid 43830437)
72. Stangelberger, A.; Schally, A.V.; Letsch, M.; Szepeshazi, K.; Nagy, A.; Halmos, G.; Kanashiro, C.A.; Corey, E.; Vessella, R. Targeted chemotherapy with cytotoxic bombesin analogue AN-215 inhibits growth of experimental human prostate cancers. Int. J. Cancer, 2006, 118, 222-229. (Pubitemid 41681603)
73. Zhang, H.; Schuhmacher, J.; Waser, B.; Wild, D.; Eisenhut, M.; Reubi, J.C.; Maecke, H.R. DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours. Eur. J. Nucl. Med. Mol. Imaging, 2007, 34, 1198-1208. (Pubitemid 47296770)
74. Lantry, L.E.; Cappelletti, E.; Maddalena, M.E.; Fox, J.S.; Feng, W.; Chen, J.; Thomas, R.; Eaton, S.M.; Bogdan, N.J.; Arunachalam, T.; Reubi, J.C.; Raju, N.; Metcalfe, E.C.; Lattuada, L.; Linder, K.E.; Swenson, R.E.; Tweedle, M.F.; Nunn, A.D. 177Lu-AMBA: synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer. J. Nucl. Med., 2006, 47, 1144-1152. (Pubitemid 47558898)
75. Maddalena, M.E.; Fox, J.; Chen, J.; Feng, W.; Cagnolini, A.; Linder, K.E.; Tweedle, M.F.; Nunn, A.D.; Lantry, L.E. 177Lu-AMBA biodistribution, radiotherapeutic efficacy, imaging, and autoradiography in prostate cancer models with low GRP-R expression. J. Nucl. Med., 2009, 50, 2017-2024.
76. Quinn, T.; Zhang, X.; Miao, Y. Targeted melanoma imaging and therapy with radiolabeled alpha-melanocyte stimulating hormone peptide analogues. G. Ital. Dermatol. Venereol., 2010, 145, 245-258.
77. Miao, Y.; Owen, N.K.; Fisher, D.R.; Hoffman, T.J.; Quinn, T.P. Therapeutic efficacy of a 188Re-labeled alpha-melanocytestimulating hormone peptide analog in murine and human melanoma-bearing mouse models. J. Nucl. Med., 2005, 46, 121-129. (Pubitemid 43086006)
78. Miao, Y.; Owen, N.K.; Whitener, D.; Gallazzi, F.; Hoffman, T.J.; Quinn, T.P. In vivo evaluation of 188Re-labeled alpha-melanocyte stimulating hormone peptide analogs for melanoma therapy. Int. J. Cancer, 2002, 101, 480-487.
79. Miao, Y.; Shelton, T.; Quinn, T.P. Therapeutic efficacy of a 177Lulabeled DOTA conjugated alpha-melanocyte-stimulating hormone peptide in a murine melanoma-bearing mouse model. Cancer Biother. Radiopharm., 2007, 22, 333-341. (Pubitemid 47067891)
80. Reubi, J.C.; Schaer, J.C.; Waser, B. Cholecystokinin(CCK)-A and CCK-B/gastrin Receptors in Human Tumors. Cancer Res., 1997, 57, 1377-1386. (Pubitemid 27152565)
81. von Guggenberg, E.; Dietrich, H.; Skvortsova, I.; Gabriel, M.; Virgolini, I.J.; Decristoforo, C. 99mTc-labelled HYNIC-minigastrin with reduced kidney uptake for targeting of CCK-2 receptorpositive tumours. Eur. J. Nucl. Med. Mol. Imaging, 2007, 34, 1209-1218. (Pubitemid 47290658)
82. Behr, T.M.; Jenner, N.; Radetzky, S.; Behe, M.; Gratz, S.; Yucekent, S.; Raue, F.; Becker, W. Targeting of cholecystokinin-B/gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin. Eur. J. Nucl. Med., 1998, 25, 424-430. (Pubitemid 28211607)
83. Roosenburg, S.; Laverman, P.; van Delft, F.L.; Boerman, O.C. Radiolabeled CCK/gastrin Peptides for Imaging and Therapy of CCK2 Receptor-expressing Tumors. Amino Acids, 2011, 41, 1049-1058.
84. Kwekkeboom, D.J.; Bakker, W.H.; Kooij, P.P.; Erion, J.; Srinivasan, A.; de Jong, M.; Reubi, J.C.; Krenning, E.P. Cholecystokinin receptor imaging using an octapeptide DTPA-CCK analogue in patients with medullary thyroid carcinoma. Eur. J. Nucl. Med., 2000, 27, 1312-1317.
85. Behr, T.M.; Behe, M.P. Cholecystokinin-B/Gastrin receptortargeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies. Semin. Nucl. Med., 2002, 32, 97-109. (Pubitemid 34311076)
86. Krenning, E.P.; Kwekkeboom, D.J.; Valkema, R.; Pauwels, S.; Kvols, L.K.; De Jong, M. Peptide receptor radionuclide therapy. Ann. N. Y. Acad. Sci., 2004, 1014, 234-245. (Pubitemid 38594811)
87. Reubi, J.C.; Waser, B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur. J. Nucl. Med. Mol. Imaging, 2003, 30, 781-793. (Pubitemid 36612963)
88. Zhang, Y.; Chen, W. Radiolabeled glucagon-like peptide-1 analogues: a new pancreatic beta-cell imaging agent. Nucl. Med. Commun., 2012, 33, 223-227.
89. Wicki, A.; Wild, D.; Storch, D.; Seemayer, C.; Gotthardt, M.; Behe, M.; Kneifel, S.; Mihatsch, M.J.; Reubi, J.C.; Macke, H.R.; Christofori, G. [Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma. Clin. Cancer Res., 2007, 13, 3696-3705. (Pubitemid 46955134)
90. Buchegger, F.; Bonvin, F.; Kosinski, M.; Schaffland, A.O.; Prior, J.; Reubi, J.C.; Blauenstein, P.; Tourwe, D.; Garcia Garayoa, E.; Bischof Delaloye, A. Radiolabeled neurotensin analog, 99mTc-NTXI, evaluated in ductal pancreatic adenocarcinoma patients. J. Nucl. Med., 2003, 44, 1649-1654. (Pubitemid 39663339)
91. Reubi, J.C.; Waser, B.; Friess, H.; Buchler, M.; Laissue, J. Neurotensin Receptors: A New Marker for Human Ductal Pancreatic Adenocarcinoma. Gut, 1998, 42, 546-550. (Pubitemid 28186573)
92. Reubi, J.C.; Macke, H.R.; Krenning, E.P. Candidates for peptide receptor radiotherapy today and in the future. J. Nucl. Med., 2005, 46 Suppl 1, 67S-75S. (Pubitemid 47619021)
93. Hennig, I.M.; Laissue, J.A.; Horisberger, U.; Reubi, J.C. Substance-P receptors in human primary neoplasms: tumoral and vascular localization. Int. J. Cancer, 1995, 61, 786-792.
94. Kneifel, S.; Bernhardt, P.; Uusijarvi, H.; Good, S.; Plasswilm, L.; Buitrago-Tellez, C.; Muller-Brand, J.; Macke, H.; Merlo, A. Individual voxelwise dosimetry of targeted 90Y-labelled substance P radiotherapy for malignant gliomas. Eur. J. Nucl. Med. Mol. Imaging, 2007, 34, 1388-1395. (Pubitemid 47312574)
95. Bergsma, H.; van Vliet, E.I.; Teunissen, J.J.; Kam, B.L.; de Herder, W.W.; Peeters, R.P.; Krenning, E.P.; Kwekkeboom, D.J. Peptide receptor radionuclide therapy (PRRT) for GEP-NETs. Best Pract. Res. Clin. Gastroenterol., 2012, 26, 867-881.
96. Wester, H.J.; Schottelius, M.; Poethko, T.; Bruus-Jensen, K.; Schwaiger, M. Radiolabeled carbohydrated somatostatin analogs: a review of the current status. Cancer Biother. Radiopharm., 2004, 19, 231-244. (Pubitemid 38685121)
97. de Jong, M.; Breeman, W.A.; Kwekkeboom, D.J.; Valkema, R.; Krenning, E.P. Tumor imaging and therapy using radiolabeled somatostatin analogues. Acc. Chem. Res., 2009, 42, 873-880.
98. Bernard, B.; Capello, A.; van Hagen, M.; Breeman, W.; Srinivasan, A.; Schmidt, M.; Erion, J.; van Gameren, A.; Krenning, E.; de Jong, M. Radiolabeled RGD-DTPA-Tyr3-octreotate for receptortargeted radionuclide therapy. Cancer Biother. Radiopharm., 2004, 19, 173-180. (Pubitemid 38685115)
99. Pfeifer, A.K.; Gregersen, T.; Gronbaek, H.; Hansen, C.P.; Muller-Brand, J.; Herskind Bruun, K.; Krogh, K.; Kjaer, A.; Knigge, U. Peptide Receptor Radionuclide Therapy with Y-DOTATOC and (177)Lu-DOTATOC in Advanced Neuroendocrine Tumors: Results from A Danish Cohort Treated in Switzerland. Neuroendocrinology, 2011, 93, 189-196.
100. Pach, D.; Sowa-Staszczak, A.; Kunikowska, J.; Krolicki, L.; Trofimiuk, M.; Stefanska, A.; Tomaszuk, M.; Glowa, B.; Mikolajczak, R.; Pawlak, D.; Jabrocka-Hybel, A.; Hubalewska-Dydejczyk, A.B. Repeated cycles of peptide receptor radionuclide therapy (PRRT)-Results and side-effects of the radioisotope (90)YDOTA TATE, (177)Lu-DOTA TATE or (90)Y/(177)Lu-DOTA TATE therapy in patients with disseminated NET. Radiother. Oncol., 2012, 102, 45-50.
101. Moorin, R.E.; Meyrick, D.P.; Rose, A. Pre-clinical evaluation of 2,3-dimercaptosuccinic acid as a radiation nephrotoxicity protective agent during radiopeptide therapy of neuroendocrine malignancy. Nucl. Med. Commun., 2007, 28, 261-266. (Pubitemid 46673202)
102. Rolleman, E.J.; Melis, M.; Valkema, R.; Boerman, O.C.; Krenning, E.P.; de Jong, M. Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues. Eur. J. Nucl. Med. Mol. Imaging, 2010, 37, 1018-1031.
103. Vegt, E.; Eek, A.; Oyen, W.J.; de Jong, M.; Gotthardt, M.; Boerman, O.C. Albumin-derived peptides efficiently reduce renal uptake of radiolabelled peptides. Eur. J. Nucl. Med. Mol. Imaging, 2010, 37, 226-234.
104. Gupta, S.K.; Singla, S.; Bal, C. Renal and hematological toxicity in patients of neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-DOTATATE. Cancer Biother. Radiopharm., 2012, 27, 593-599.
105. de Jong, M.; Breeman, W.A.; Valkema, R.; Bernard, B.F.; Krenning, E.P. Combination radionuclide therapy using 177Lu-and 90Y-labeled somatostatin analogs. J. Nucl. Med., 2005, 46 Suppl 1, 13S-17S. (Pubitemid 47619014)
106. Kunikowska, J.; Krolicki, L.; Hubalewska-Dydejczyk, A.; Mikolajczak, R.; Sowa-Staszczak, A.; Pawlak, D. Clinical results of radionuclide therapy of neuroendocrine tumours with 90Yonuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option? Eur. J. Nucl. Med. Mol. Imaging, 2011, 38, 1788-1797.
107. Villard, L.; Romer, A.; Marincek, N.; Brunner, P.; Koller, M.T.; Schindler, C.; Ng, Q.K.; Macke, H.R.; Muller-Brand, J.; Rochlitz, C.; Briel, M.; Walter, M.A. Cohort study of somatostatin-based radiopeptide therapy with (90)Y-DOTA-TOC versus (90)Y-DOTA-TOC plus (177)Lu-DOTA-TOC in neuroendocrine cancers. J. Clin. Oncol., 2012, 30, 1100-1106.
108. Limouris, G.S.; Chatziioannou, A.; Kontogeorgakos, D.; Mourikis, D.; Lyra, M.; Dimitriou, P.; Stavraka, A.; Gouliamos, A.; Vlahos, L. Selective hepatic arterial infusion of In-111-DTPA-Phe1-octreotide in neuroendocrine liver metastases. Eur. J. Nucl. Med. Mol. Imaging, 2008, 35, 1827-1837.
109. McStay, M.K.; Maudgil, D.; Williams, M.; Tibballs, J.M.; Watkinson, A.F.; Caplin, M.E.; Buscombe, J.R. Large-volume Liver Metastases from Neuroendocrine Tumors: Hepatic Intraarterial 90Y-DOTAlanreotide As Effective Palliative Therapy. Radiology, 2005, 237, 718-726. (Pubitemid 41507917)
110. Claringbold, P.G.; Brayshaw, P.A.; Price, R.A.; Turner, J.H. Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imaging, 2011, 38, 302-311.
111. de Jong, M.; Kwekkeboom, D.; Valkema, R.; Krenning, E.P. Radiolabelled peptides for tumour therapy: current status and future directions. plenary lecture at the EANM 2002. Eur. J. Nucl. Med. Mol. Imaging, 2003, 30, 463-469. (Pubitemid 36692876)
112. Cordier, D.; Forrer, F.; Kneifel, S.; Sailer, M.; Mariani, L.; Macke, H.; Muller-Brand, J.; Merlo, A. Neoadjuvant targeting of glioblastoma multiforme with radiolabeled DOTAGA-substance P-results from a phase I study. J. Neurooncol., 2010, 100, 129-136.
113. Waitz, D.; Putzer, D.; Kostron, H.; Virgolini, I.J. Treatment of High-grade Glioma with Radiolabeled Peptides. Methods, 2011, 55, 223-229.
114. Walrand, S.; Flux, G.D.; Konijnenberg, M.W.; Valkema, R.; Krenning, E.P.; Lhommel, R.; Pauwels, S.; Jamar, F. Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: 86Y or 90Y imaging? Eur. J. Nucl. Med. Mol. Imaging, 2011, 38 Suppl 1, S57-68.
115. Chinol, M.; Bodei, L.; Cremonesi, M.; Paganelli, G. Receptormediated radiotherapy with Y-DOTA-DPhe-Tyr-octreotide: the experience of the european institute of oncology group. Semin. Nucl. Med., 2002, 32, 141-147. (Pubitemid 34311080)
116. Bartolomei, M.; Bodei, L.; De Cicco, C.; Grana, C.M.; Cremonesi, M.; Botteri, E.; Baio, S.M.; Arico, D.; Sansovini, M.; Paganelli, G. Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma. Eur. J. Nucl. Med. Mol. Imaging, 2009, 36, 1407-1416.
117. Sward, C.; Bernhardt, P.; Ahlman, H.; Wangberg, B.; Forssell-Aronsson, E.; Larsson, M.; Svensson, J.; Rossi-Norrlund, R.; Kolby, L. 177Lu-DOTA 0-Tyr 3-octreotate treatment in patients with disseminated gastroenteropancreatic neuroendocrine tumors: the value of measuring absorbed dose to the kidney. World J. Surg., 2010, 34, 1368-1372.
118. Garkavij, M.; Nickel, M.; Sjogreen-Gleisner, K.; Ljungberg, M.; Ohlsson, T.; Wingardh, K.; Strand, S.E.; Tennvall, J. 177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: analysis of dosimetry with impact on future therapeutic strategy. Cancer, 2010, 116, 1084-1092.
119. Bodei, L.; Cremonesi, M.; Grana, C.M.; Fazio, N.; Iodice, S.; Baio, S.M.; Bartolomei, M.; Lombardo, D.; Ferrari, M.E.; Sansovini, M.; Chinol, M.; Paganelli, G. Peptide receptor radionuclide therapy with (177)Lu-DOTATATE: the IEO phase I-II study. Eur. J. Nucl. Med. Mol. Imaging, 2011, 38, 2125-2135.